Compare General Motors Company (GM) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Kymera Therapeutics Inc. Common Stock — how do they compare? General Motors Company trades at $83.25 (market cap $72.87B), while Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B). The key difference: General Motors Company is far larger — about 8.2× Kymera Therapeutics Inc. Common Stock's market cap, and General Motors Company pays a 0.87% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| GM | KYMR | |
|---|---|---|
Market Cap | $72.87B | $8.88B |
Volume | 6,101,486 | 1,028,790 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $127.31 |
52-Week Low | $57.34 | $55.80 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $175.85B | $8.27B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $84.00, up 1.98% with a bullish technical signal. The company shows strong cash flow generation ($26.9B operating cash flow in 2025) but faces margin compression with net income margin declining to 1.05%. Recent Q3 2026 sales declined 5.5% as EV demand weakens, though GM benefits from $20.4B in projected savings from eased fuel economy rules. Analyst consensus remains positive with 67% buy ratings and $102.33 price target representing 22% upside.
GM presents a value opportunity with attractive valuation (P/S 0.42x) and strong analyst support, but faces near-term headwinds from declining vehicle sales, margin pressure, and competitive threats from Asian automakers. The stock's investment thesis hinges on successful EV transition execution and cost savings realization amid challenging market conditions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
